Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeneDx Holdings Corp WGS

Financial Services Healthcare
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing... see more

Recent & Breaking News (NDAQ:WGS)

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

GlobeNewswire February 28, 2023

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

GlobeNewswire February 21, 2023

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

GlobeNewswire February 16, 2023

GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

GlobeNewswire January 31, 2023

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

GlobeNewswire January 30, 2023

GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering

GlobeNewswire January 27, 2023

GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering

GlobeNewswire January 26, 2023

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

GlobeNewswire January 9, 2023

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 30, 2022

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

GlobeNewswire December 5, 2022

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

GlobeNewswire November 14, 2022

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire November 7, 2022

Sema4 Holdings Corp. Class Action: Levi & Korsinsky Reminds Sema4 Holdings, Corp. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2022 - SMFR

Newsfile November 7, 2022

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

PR Newswire November 7, 2022

Deadline Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders of Last Few Hours to Actively Participate

Business Wire November 7, 2022

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Newsfile November 7, 2022

SMFR ALERT: Hagens Berman, National Trial Attorneys, Alerts Sema4 Holdings (SMFR) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

Newsfile November 7, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Sema4 Holdings Corp. Investors of a Lead Plaintiff Deadline of November 7, 2022

PR Newswire November 7, 2022

24-Hour Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 6, 2022

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 7, 2022 in Sema4 Holdings Corp. Lawsuit - SMFR

Newsfile November 6, 2022